The North American Collaborative Study of Maternal Phenylketonuria

Status report 1993

R. Koch, H. L. Levy, Reuben Matalon, B. Rouse, W. Hanley, C. Azen

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Neonatal screening for phenylketonuria (PKU) has created an unexpected problem as females with PKU are reaching childbearing age. Surveys have revealed that maternal phenylalanine blood concentrations above 1200 μmol/L are associated with microcephaly, mental retardation, congenital heart defects, and intrauterine growth retardation among their offspring. It is estimated that as many as 3000 hyperphenylalaninemic females may be at risk for producing these fetal abnormalities. To examine this problem, the North American Maternal PKU Collaborative Study has been developed to evaluate the efficacy of a phenylalanine-restricted diet in reducing fetal morbidity. Preliminary findings indicate that phenylalanine restriction should begin before conception for females with PKU planning a pregnancy. Dietary control should maintain maternal blood phenylalanine levels between 120 and 360 μmol/L and should provide adequate energy, protein, vitamin, and mineral intake. Pregnant hyperphenylalaninemic females who achieved metabolic control after conception or by the 10th week of pregnancy had a better offspring outcome than anticipated.

Original languageEnglish (US)
Pages (from-to)1224-1230
Number of pages7
JournalAmerican Journal of Diseases of Children
Volume147
Issue number11
StatePublished - 1993
Externally publishedYes

Fingerprint

Maternal Phenylketonuria
Phenylalanine
Phenylketonurias
Mothers
Reducing Diet
Neonatal Screening
Pregnancy
Microcephaly
Fetal Growth Retardation
Congenital Heart Defects
Vitamins
Intellectual Disability
Minerals
Morbidity
Proteins

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

The North American Collaborative Study of Maternal Phenylketonuria : Status report 1993. / Koch, R.; Levy, H. L.; Matalon, Reuben; Rouse, B.; Hanley, W.; Azen, C.

In: American Journal of Diseases of Children, Vol. 147, No. 11, 1993, p. 1224-1230.

Research output: Contribution to journalArticle

Koch, R, Levy, HL, Matalon, R, Rouse, B, Hanley, W & Azen, C 1993, 'The North American Collaborative Study of Maternal Phenylketonuria: Status report 1993', American Journal of Diseases of Children, vol. 147, no. 11, pp. 1224-1230.
Koch, R. ; Levy, H. L. ; Matalon, Reuben ; Rouse, B. ; Hanley, W. ; Azen, C. / The North American Collaborative Study of Maternal Phenylketonuria : Status report 1993. In: American Journal of Diseases of Children. 1993 ; Vol. 147, No. 11. pp. 1224-1230.
@article{0499f02ec54c4f68afb1b9261a3e85bf,
title = "The North American Collaborative Study of Maternal Phenylketonuria: Status report 1993",
abstract = "Neonatal screening for phenylketonuria (PKU) has created an unexpected problem as females with PKU are reaching childbearing age. Surveys have revealed that maternal phenylalanine blood concentrations above 1200 μmol/L are associated with microcephaly, mental retardation, congenital heart defects, and intrauterine growth retardation among their offspring. It is estimated that as many as 3000 hyperphenylalaninemic females may be at risk for producing these fetal abnormalities. To examine this problem, the North American Maternal PKU Collaborative Study has been developed to evaluate the efficacy of a phenylalanine-restricted diet in reducing fetal morbidity. Preliminary findings indicate that phenylalanine restriction should begin before conception for females with PKU planning a pregnancy. Dietary control should maintain maternal blood phenylalanine levels between 120 and 360 μmol/L and should provide adequate energy, protein, vitamin, and mineral intake. Pregnant hyperphenylalaninemic females who achieved metabolic control after conception or by the 10th week of pregnancy had a better offspring outcome than anticipated.",
author = "R. Koch and Levy, {H. L.} and Reuben Matalon and B. Rouse and W. Hanley and C. Azen",
year = "1993",
language = "English (US)",
volume = "147",
pages = "1224--1230",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "11",

}

TY - JOUR

T1 - The North American Collaborative Study of Maternal Phenylketonuria

T2 - Status report 1993

AU - Koch, R.

AU - Levy, H. L.

AU - Matalon, Reuben

AU - Rouse, B.

AU - Hanley, W.

AU - Azen, C.

PY - 1993

Y1 - 1993

N2 - Neonatal screening for phenylketonuria (PKU) has created an unexpected problem as females with PKU are reaching childbearing age. Surveys have revealed that maternal phenylalanine blood concentrations above 1200 μmol/L are associated with microcephaly, mental retardation, congenital heart defects, and intrauterine growth retardation among their offspring. It is estimated that as many as 3000 hyperphenylalaninemic females may be at risk for producing these fetal abnormalities. To examine this problem, the North American Maternal PKU Collaborative Study has been developed to evaluate the efficacy of a phenylalanine-restricted diet in reducing fetal morbidity. Preliminary findings indicate that phenylalanine restriction should begin before conception for females with PKU planning a pregnancy. Dietary control should maintain maternal blood phenylalanine levels between 120 and 360 μmol/L and should provide adequate energy, protein, vitamin, and mineral intake. Pregnant hyperphenylalaninemic females who achieved metabolic control after conception or by the 10th week of pregnancy had a better offspring outcome than anticipated.

AB - Neonatal screening for phenylketonuria (PKU) has created an unexpected problem as females with PKU are reaching childbearing age. Surveys have revealed that maternal phenylalanine blood concentrations above 1200 μmol/L are associated with microcephaly, mental retardation, congenital heart defects, and intrauterine growth retardation among their offspring. It is estimated that as many as 3000 hyperphenylalaninemic females may be at risk for producing these fetal abnormalities. To examine this problem, the North American Maternal PKU Collaborative Study has been developed to evaluate the efficacy of a phenylalanine-restricted diet in reducing fetal morbidity. Preliminary findings indicate that phenylalanine restriction should begin before conception for females with PKU planning a pregnancy. Dietary control should maintain maternal blood phenylalanine levels between 120 and 360 μmol/L and should provide adequate energy, protein, vitamin, and mineral intake. Pregnant hyperphenylalaninemic females who achieved metabolic control after conception or by the 10th week of pregnancy had a better offspring outcome than anticipated.

UR - http://www.scopus.com/inward/record.url?scp=0027442890&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027442890&partnerID=8YFLogxK

M3 - Article

VL - 147

SP - 1224

EP - 1230

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 11

ER -